A phase I/II trial in patients with metastatic gastrointestinal epithelial cancer administering tumor‐infiltrating lymphocytes in which the gene encoding CISH was inactivated using the CRISPR/Cas9 system. The gene discussed is CISH; the disease is neoplasm.